The first domestic new anticancer drug, furaquinotinib, is on the market. The market of tinib is changing soon!

Recently, the first phase 3 clinical study of fqtinib, developed independently by Hutchison Whampoa, has reached the end point and been put on the market for approval, which means that another heavy anti-cancer new drug is about to be launched, and this drug is the first anti-cancer target drug independently developed by Chinese scientists, and it is an important sign that China's anti-cancer target drug has made progress from imitation, independent research and development to independent research and development What is fluquinotinib? It is a highly selective long-acting VEGFR inhibitor Its indications include colorectal cancer and non-small cell lung cancer Clinical studies show that the drug has many advantages, such as low toxicity, good drug tolerance and strong effect In addition, the clinical study on the treatment of gastric cancer and lung cancer with fqtinib and other drugs is also in progress Furquitinib is independently developed by Hutchison China medical technology company, a subsidiary of Li Ka Shing The company started the research and development of eight new anti-cancer drugs including furquitinine 17 years ago, and has invested more than 400 million US dollars (3.5 billion Hong Kong dollars) At present, among the domestic enterprises engaged in the research and development of new anticancer drugs, many self-developed new drugs have entered the clinical experiment stage Among them, anlotinib, which is independently developed by Zhengda Tianqing, is currently undergoing phase III clinical trials Cancer is one of the most important diseases threatening the survival of human beings In the next 20 years, the number of new cancer cases is expected to increase by 70% The incidence rate of cancer is close to the world level, but the mortality rate is higher than the world level In recent years, the incidence rate of cancer has declined in the United States Its 5 year survival rate is 60%-70%, while the 5 year survival rate of cancer patients in China is about 30% Because of the advantages of highly selective killing of cancer cells and little damage to normal cells, anticancer targeting drugs are becoming the first-line anticancer drugs To improve the role of targeted drug precision treatment in cancer diagnosis and treatment will become an important means to improve the survival rate of cancer patients in China At present, the anti-cancer target drugs in the domestic market are mainly monoclonal antibodies and TiNi drugs According to Zhongkang CMH data, in 2016, the sales of monoclonal anti-tumor drugs accounted for 6.71% of the total sales of anti-tumor drugs, and the sales of TiNi anti-tumor drugs accounted for 5.98% of the total sales of anti-tumor drugs In addition, sorafenib accounted for 0.98% of the sales of liver cancer targeting drugs and 0.36% of bortezomib used for the treatment of multiple myeloma Data source: market situation of TiNi drugs in China of Zhongkang CMH fuquinotinib belongs to TiNi drugs of anticancer targeting drugs At present, there are 11 kinds of TiNi drugs sold in China Many kinds of TiNi drugs have not been approved for market, but they have been in clinical trials in China Most of the price of TiNi drugs is in the level of ten thousand yuan According to the CMH data of Zhongkang, the unit price of 5 kinds of TiNi is more than ten thousand yuan, among which the unit price of clozatinib is 53090.6 yuan / 0.2g * 60s, which makes many cancer patients flinch Targeted therapy is also known as "gold eating" because of its high price Data source: from the perspective of sales volume of Zhongkang CMH, the sales volume of erlotinib, dasatinib and other products with high price is higher, indicating that price is not the most important influencing factor of sales volume of TiNi drugs The main factors influencing the sales volume of TiNi drugs may be: 1 The number of patients; 2 Alternative drugs; 3 The therapeutic effect of drugs According to the comprehensive price and sales volume, although the overall sales volume of TiNi drugs is not high, because of the high price level, the sales volume of TiNi drugs only needs a small amount to reach a large amount, so in recent years, TiNi drugs have become the drugs that many pharmaceutical companies are competing to develop Data source: in terms of time dimension, the sales volume of most TiNi drugs did not change significantly with time Because the anti-cancer targeted drugs have good therapeutic effect on a small number of patients, but they are easy to produce drug resistance, so the problem of low viscosity and high mobility of patients may occur under the joint action of new patients and abandoned patients Data source: among the domestic enterprises selling Tinian drugs, foreign-funded enterprises account for 85.72%, which is an absolute advantage Most of the TiNi drugs sold by Chinese enterprises are imitations, while apatinib of Hengrui pharmaceutical is independently developed At present, there are six Chinese enterprises selling TiNi drugs: Zhengda Tianqing, Hengrui pharmaceutical, hausen pharmaceutical, Shiyao group, China Resources and Beida pharmaceutical Data source: by comparing the price of TiNi drugs sold by Chinese and foreign enterprises, Zhongkang CMH found that the price of imported TiNi drugs was much higher than that of domestic TiNi drugs Take two kinds of TiNi drugs, dasatinib and imatinib, which are both imported and sold in China, for example, the prices of domestic drugs and imported drugs of similar products are quite different The import price of dasatinib 20mg * 60s is 6.3 times of the domestic price, and the import price of 50mg * 60s is 6.5 times of the domestic price The import price of imatinib 0.1g * 60s is 3.5 times of the domestic price Data source: with the price advantage of domestic Tinian drugs, the improvement of domestic R & D strength will accelerate the import substitution of Tinian drugs Hutchison Whampoa's new drug, furquitinib, has not yet been priced, but Christian Hogg, chief executive of Hutchison Whampoa, said the new drug will be available at a price that most patients can accept.